Catherine C. Coombs, MD

Articles

Clinical Pearls and Impacts to Practice from EHA 2024

September 5th 2024

The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.

Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies

August 29th 2024

Key opinion leaders provide concise insights on the potential of bispecific antibodies as emerging novel therapeutic agents for relapsed/refractory chronic lymphocytic leukemia.

Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL

August 29th 2024

Nicole Lamanna, MD, offers expert insights on the emerging data for second-generation BCL2 inhibitors in relapsed/refractory chronic lymphocytic leukemia, highlighting recent advancements in the field.

Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673

August 22nd 2024

Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.

EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL

August 22nd 2024

The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.

TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices

August 15th 2024

Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.

Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice

August 15th 2024

A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.

Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLL

August 13th 2024

The panel concludes its discussion with a look to the future of CLL treatment, focusing on emerging novel agents and exciting clinical research.

Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing

August 12th 2024

Key opinion leaders examine recent evidence on acquired BTK inhibitor resistance in chronic lymphocytic leukemia and analyze its implications for treatment sequencing decisions in clinical practice.

Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib

August 12th 2024

An oncology specialist outlines their general approach to managing treatment-related atrial fibrillation in patients receiving BTK inhibitor therapy, incorporating insights from recent clinical data to inform their management strategies.

Updates in CLL Treatment Strategies with Noncovalent BTKis

August 6th 2024

Highlighting recent clinical trial data on pirtobrutinib in patients with chronic lymphocytic leukemia, the panel shares their experience utilizing it in clinical practice.

Management Strategies for BTKi-Related CVAEs in CLL

August 6th 2024

Bita Fakhri, MD, MPH, shares her general approach to managing common cardiovascular adverse events associated with BTK inhibitors in patients with chronic lymphocytic leukemia.

Approach to Hypertension Management With BTKi Treatment

August 5th 2024

Medical experts deliberate on strategies for managing newly developed or exacerbated hypertension in patients undergoing treatment with BTK inhibitors for chronic lymphocytic leukemia.

Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities

August 5th 2024

Experts analyze recent real-world evidence on treatment patterns, focusing on the strategies and outcomes of switching and sequencing therapies in chronic lymphocytic leukemia patients.

Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications

July 30th 2024

The panel addresses the intricacies of treating patients with chronic lymphocytic leukemia who experience treatment resistance.

Navigating 2L Treatment Options in CLL

July 30th 2024

Experts on chronic lymphocytic leukemia discuss treatment practices for patients with relapsed/refractory CLL and provide insights on the role for venetoclax in patients who previously received BTK inhibitors.

BTKi Intolerance in Real-world Practice & Management Strategy

July 29th 2024

Key opinion leaders compare and contrast the most frequently observed causes of BTK inhibitor intolerance in clinical practice among patients treated with ibrutinib, acalabrutinib, or zanubrutinib.

How Experts View MAIC Data That was Presented at EHA 2024

July 29th 2024

A panel of experts examines and interprets the most recent matching-adjusted indirect comparison (MAIC) data presented at the European Hematology Association 2024 conference, focusing on the comparative analysis of the ASCEND and ALPINE trials in chronic lymphocytic leukemia treatment.

Patient with R/R CLL Treated with 2L Venetoclax Therapy

July 23rd 2024

A hematology and oncology specialist presents the case of a 66-year-old man with chronic lymphocytic leukemia.

Expert Insights for Long-Term Treatment Planning in CLL

July 23rd 2024

Catherine C. Coombs, MD, outlines considerations for long-term treatment planning, particularly in younger patients with chronic lymphocytic leukemia.